Cabergoline and mitral regurgitation [10]

New England Journal of Medicine

Volumn 354, Issue 4, 2006, Pages 420-

  Delgrange, Etienne ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID;

AGE DISTRIBUTION; AGED; CASE REPORT; DOSE RESPONSE; FIBROSIS; HUMAN; HYPERPROLACTINEMIA; LETTER; MALE; MITRAL VALVE REGURGITATION; PARKINSON DISEASE; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

AGED; DOPAMINE AGONISTS; ERGOLINES; HUMANS; HYPERPROLACTINEMIA; MALE; MITRAL VALVE INSUFFICIENCY; PARKINSON DISEASE;

EID: 31344464941     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053329     Document Type: Letter

References (3)

1. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7.
2. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998;339:1130-43.
3. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023-33.